$12.60
0.40%
Nasdaq, Sep 17, 04:00 pm EDT. Closed.
ISIN
US61225M1027
Symbol
GLUE

Monte Rosa Therapeutics Inc Stock price

$12.60
-2.78 18.08% 1M
-3.43 21.40% 6M
-3.08 19.64% YTD
+6.24 98.11% 1Y
+6.58 109.30% 3Y
-18.13 59.00% 5Y
-8.58 40.51% 10Y
-8.58 40.51% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
-0.05 0.40%
ISIN
US61225M1027
Symbol
GLUE
Industry

Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$458.1m
Net debt
positive
Cash
$621.1m
Shares outstanding
85.2m
Valuation (TTM | estimate)
P/E
negative
P/S
37.6 | 38.7
EV/Sales
16.0 | 16.4
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
52.0%
Return on Equity
-16.6%
ROCE
-28.8%
ROIC
-438.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$28.7m | $27.9m
EBITDA
$-173.7m
EBIT
$-181.9m
Net Income
$-161.1m
Free Cash Flow
$-32.1m
Growth (TTM | estimate)
Revenue
-83.9% | -77.5%
EBITDA
-845.6%
EBIT
-1,315.7%
Net Income
-766.6%
Free Cash Flow
-234.5%
Margin
Gross
-
EBITDA
-604.8%
EBIT
-633.0%
Net
-560.9%
Free Cash Flow
-111.7%
More
EPS
$-1.6
FCF per Share
$-0.4
Short interest
21.5%
Employees
187
Rev per Employee
$660.0k

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Monte Rosa Therapeutics Inc

Jun '26
+/-
%
29 29
84% 84%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
18% 18%
139%
- Research and Development Expense 171 171
32% 32%
594%
-174 -174
846% 846%
-605%
- Depreciation and Amortization 8.13 8.13
3% 3%
28%
EBIT (Operating Income) EBIT -182 -182
1,316% 1,316%
-633%
Net Profit -161 -161
767% 767%
-561%

In millions USD.

Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monte Rosa Therapeutics Inc Stock News

Neutral
GlobeNewsWire
9 days ago
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Ro...
Neutral
GlobeNewsWire
15 days ago
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.
Neutral
GlobeNewsWire
24 days ago
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office United States
CEO Dr. Warmuth
Employees 187
Founded 2019
Website www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today